-
1دورية أكاديمية
المؤلفون: Johnston, SRD, Hegg, R, Im, S-A, Park, IH, Burdaeva, O, Kurteva, G, Press, MF, Tjulandin, S, Iwata, H, Simon, SD, Kenny, S, Sarp, S, Izquierdo, MA, Williams, LS, Gradishar, WJ
المساهمون: Johnston, Stephen, Marsden
مصطلحات موضوعية: Humans, Breast Neoplasms, Receptor, erbB-2, Antineoplastic Agents, Aromatase Inhibitors, Postmenopause, Adult, Aged, 80 and over, Middle Aged, Female, Trastuzumab, Lapatinib
وصف الملف: Print-Electronic; 748; image/png
العلاقة: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 36 (8), pp. 741 - 748; https://repository.icr.ac.uk/handle/internal/1293Test
الإتاحة: https://doi.org/10.1200/jco.2017.74.7824Test
https://repository.icr.ac.uk/handle/internal/1293Test -
2
المؤلفون: Ursa Brown-Glaberman, Maaike de Boer, Denise A. Yardley, Jeffrey L. Nordstrom, Sung Bae Kim, Erik Jakobsen, Jean Marc Ferrero, Scott Koenig, William J. Gradishar, Seock-Ah Im, Javier Cortes, Gail S. Wright, Ezio Bonvini, Cristina Saura, Michelino De Laurentiis, Bella Kaufman, Sutton Edlich, Hope S. Rugo, Christelle Levy, Fatima Cardoso, Antonino Musolino, Peter A. Fasching, Mark D. Pegram, Orit Freedman, Santiago Escrivá-de-Romaní, Shengyan Hong, Rinat Yerushalmi, Edwin P. Rock, Giuseppe Curigliano, Katarína Petráková
المساهمون: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Rugo, H. S., Im, S. -A., Cardoso, F., Cortes, J., Curigliano, G., Musolino, A., Pegram, M. D., Wright, G. S., Saura, C., Escriva-De-Romani, S., De Laurentiis, M., Levy, C., Brown-Glaberman, U., Ferrero, J. -M., De Boer, M., Kim, S. -B., Petrakova, K., Yardley, D. A., Freedman, O., Jakobsen, E. H., Kaufman, B., Yerushalmi, R., Fasching, P. A., Nordstrom, J. L., Bonvini, E., Koenig, S., Edlich, S., Hong, S., Rock, E. P., Gradishar, W. J., Institut Català de la Salut, [Rugo HS] University of California San Francisco Helen Diller Family Comprehensive Cancer Center. [Im SA] Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. [Cardoso F] Champalimaud Clinical Center/Champalimaud Foundation, Breast Unit, Lisbon, Portugal. [Cortés J] IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Curigliano G] European Institute of Oncology, IRCCS, Division of Early Drug Development, University of Milano, Milan, Italy. [Musolino A] Department of Medicine and Surgery, University of Parma, Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy. [Saura C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus
المصدر: SOPHIA Study Group 2021, ' Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast Cancer : A Phase 3 Randomized Clinical Trial ', JAMA Oncology, vol. 7, no. 4, pp. 573-584 . https://doi.org/10.1001/jamaoncol.2020.7932Test
JAMA Oncology, 7(4), 573-584. American Medical Association
JAMA Oncol
Scientiaمصطلحات موضوعية: Oncology, Relative risk reduction, Cancer Research, MONOCLONAL-ANTIBODY, Receptor, ErbB-2, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Other subheadings::Other subheadings::/drug therapy [Other subheadings], Ado-Trastuzumab Emtansine, RECOMMENDATIONS, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, 030212 general & internal medicine, Original Investigation, Aged, 80 and over, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], benefit, Hazard ratio, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Antibodies, Monoclonal, Middle Aged, CHEMOTHERAPY, Chemotherapy regimen, 030220 oncology & carcinogenesis, Female, Pertuzumab, medicine.drug, Adult, medicine.medical_specialty, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Breast Neoplasms, IMMUNITY, survival, Quimioteràpia combinada, 03 medical and health sciences, Breast cancer, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Internal medicine, medicine, Humans, Aged, C RECEPTOR POLYMORPHISMS, therapy, business.industry, association, diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], medicine.disease, Interim analysis, Mama - Càncer - Tractament, Avaluació de resultats (Assistència sanitària), business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::beae17ac62d0e63c250dbce6359002edTest
https://doi.org/10.1001/jamaoncol.2020.7932Test -
3
المؤلفون: Christian Jackisch, Seock-Ah Im, Michelino De Laurentiis, Jean-Yves Pierga, Mahesh Shivhare, Ramon Colomer, Kyung Hae Jung, Tanja Badovinac Crnjevic, Alexandra Hogea, Daniil Stroyakovskii, Sarah Heeson, Antoinette R. Tan, Zbigniew Nowecki, André Mattar, Whitney P. Kirschbrown, Christian Schem, Eleonora Restuccia
المساهمون: Tan, A. R., Im, S. -A., Mattar, A., Colomer, R., Stroyakovskii, D., Nowecki, Z., De Laurentiis, M., Pierga, J. -Y., Jung, K. H., Schem, C., Hogea, A., Badovinac Crnjevic, T., Heeson, S., Shivhare, M., Kirschbrown, W. P., Restuccia, E., Jackisch, C.
المصدر: The Lancet. Oncology. 22(1)
مصطلحات موضوعية: 0301 basic medicine, Adult, medicine.medical_specialty, Time Factors, Receptor, ErbB-2, medicine.medical_treatment, Injections, Subcutaneous, Population, Phases of clinical research, Hyaluronoglucosaminidase, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Loading dose, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Trastuzumab, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Biomarkers, Tumor, Humans, education, Neoadjuvant therapy, Neoplasm Staging, education.field_of_study, business.industry, Middle Aged, medicine.disease, Chemotherapy regimen, Neoadjuvant Therapy, 030104 developmental biology, Treatment Outcome, Oncology, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Pertuzumab, business, Febrile neutropenia, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99e575a2761394ec388f6b5a6dee91bfTest
https://pubmed.ncbi.nlm.nih.gov/33539750Test -
4
المؤلفون: Haiying Liu, Sanne de Haas, Seock-Ah Im, Francisco J. Esteva, Jigna Shah, Sherene Loi, Monika Patre, C. Lambertini, Sung Bae Kim, Yifan Wang, Mark Beresford, Aruna Mani, Leisha A. Emens, Roberto Salgado, Cristina Saura, Michelino De Laurentiis
المساهمون: Emens, L. A., Esteva, F. J., Beresford, M., Saura, C., De Laurentiis, M., Kim, S. -B., Im, S. -A., Wang, Y., Salgado, R., Mani, A., Shah, J., Lambertini, C., Liu, H., de Haas, S. L., Patre, M., Loi, S.
المصدر: The Lancet. Oncology. 21(10)
مصطلحات موضوعية: 0301 basic medicine, Male, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Receptor, ErbB-2, Population, Programmed Cell Death 1 Receptor, Phases of clinical research, Breast Neoplasms, Placebo, Ado-Trastuzumab Emtansine, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Agents, Immunological, Double-Blind Method, Atezolizumab, Trastuzumab, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, education, Adverse effect, education.field_of_study, business.industry, Middle Aged, medicine.disease, Metastatic breast cancer, Survival Analysis, 030104 developmental biology, Treatment Outcome, Oncology, chemistry, Trastuzumab emtansine, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Female, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6df8ea55582f078b15ed0a54a5bdc723Test
https://pubmed.ncbi.nlm.nih.gov/33002436Test